Retro Biosciences is raising a $1bn round to fund the artificial intelligence-powered biotech’s mission to increase human lifespan by a decade, starting by getting its first drug into trials this year ...
(As for the wild superintelligence rumors, let’s leave that to OpenAI CEO SamAltman to address: “twitter hype is out of control again,” he posted on January 20. “pls chill and cut your ...